Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

by Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi, Alan Menter
Published 2019-11-01

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.

by James G Krueger, Mayte Suárez-Fariñas, Inna Cueto, Artemis Khacherian, Robert Matheson, Lawrence C Parish, Craig Leonardi, Denise Shortino, Akanksha Gupta, Jonathan Haddad, George P Vlasuk, Eric W Jacobson
Published 2015-01-01

Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis.

by Knut M Wittkowski, Craig Leonardi, Alice Gottlieb, Alan Menter, Gerald G Krueger, Paul W Tebbey, Jennifer Belasco, Razieh Soltani-Arabshahi, John Gray, Liz Horn, James G Krueger, International Psoriasis Council
Published 2011-01-01

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp
Published 2020-03-01